Latest Breaking News On - Seema amin - Page 1 : comparemela.com

 E-Mail Boston, Mass. Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches. Now, investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. The team, led by Beth Israel Deaconess Medical Center s (BIDMC) Rupal Bhatt, MD, PhD, and University College Cork, Ireland s Thomas Walther, PhD, published

United statesDana farber cancer instituteAndrew mooreChun hau chenCarol ocallaghanSabina signorettiMaura naughtonRupal bhattSeema aminZiad bakounyRuchi saxenaPatrick neset joslinPrateek khannaPaul catalanoThomas waltherManoj bhasin